Oxford Immunotec Global PLC (NASDAQ:OXFD) Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global PLC stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the transaction, the director now owns 17,778 shares in the company, valued at $237,336.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). Oxford Immunotec Global PLC had a negative net margin of 45.74% and a negative return on equity of 40.44%. The company had revenue of $26.10 million during the quarter, compared to the consensus estimate of $25.05 million. During the same quarter in the prior year, the firm earned ($0.29) earnings per share. The firm’s revenue was up 35.9% compared to the same quarter last year.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/02/oxford-immunotec-global-plc-oxfd-director-richard-a-sandberg-sells-3000-shares.html.

Several hedge funds have recently modified their holdings of the company. Nationwide Fund Advisors increased its position in shares of Oxford Immunotec Global PLC by 1.9% during the first quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock worth $213,000 after acquiring an additional 254 shares in the last quarter. American International Group Inc. increased its position in shares of Oxford Immunotec Global PLC by 7.1% during the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after acquiring an additional 904 shares in the last quarter. Parkwood LLC increased its position in shares of Oxford Immunotec Global PLC by 12.9% during the second quarter. Parkwood LLC now owns 12,799 shares of the company’s stock worth $215,000 after acquiring an additional 1,465 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Oxford Immunotec Global PLC by 8.8% during the second quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock worth $313,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Voya Investment Management LLC increased its position in shares of Oxford Immunotec Global PLC by 16.0% during the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after acquiring an additional 1,845 shares in the last quarter. 79.21% of the stock is owned by institutional investors.

A number of brokerages have issued reports on OXFD. Robert W. Baird reissued a “buy” rating and set a $20.00 target price on shares of Oxford Immunotec Global PLC in a research note on Wednesday. Piper Jaffray Companies decreased their target price on shares of Oxford Immunotec Global PLC from $26.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday. BTIG Research set a $21.00 target price on shares of Oxford Immunotec Global PLC and gave the company a “buy” rating in a research note on Tuesday. Zacks Investment Research lowered shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, ValuEngine lowered shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Oxford Immunotec Global PLC currently has a consensus rating of “Hold” and a consensus price target of $19.75.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Insider Buying and Selling by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.